Lucrative Novo Nordisk business segment suffers headwind

Business squeezed by the succes of the diabetes and obesity business,” says analyst.
Photo: Jacob Gronholt-pedersen
Photo: Jacob Gronholt-pedersen
by marketwire

Things are going south at Novo Nordisk in the business area with the umbrella term rare diseases. CEO Lars Fruergaard is having problems with the production of the drug Norditropin, which is hampering sales of the otherwise lucrative growth hormone, writes Danish daily Jyllands-Posten.

Already a subscriber?Log in here

Read the whole article

Get access for 14 days for free. No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.

With your free trial you get:

  • Access all locked articles
  • Receive our daily newsletters
  • Access our app
  • Must be at least 8 characters, including three of: Uppercase, lowercase, numbers, symbols
    Must contain at least 2 characters
    Must contain at least 2 characters

    Get full access for you and your coworkers

    Start a free company trial today

    Share article

    Sign up for our newsletter

    Stay ahead of development by receiving our newsletter on the latest sector knowledge.

    Newsletter terms

    Front page now

    Further reading